This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bull of the Day: Mesa Laboratories (MLAB)
by Kevin Cook
Key M&A boosts sales & EPS, opens path to new business with Clinical Genomics Division
PacBio (PACB) Partners with ERGA, Boosts Biodiversity Research
by Zacks Equity Research
PacBio's (PACB) collaboration with ERGA will help scientists to take the first important step toward creating high-quality genetic maps of each plant and animal species in a reliable manner.
PacBio (PACB) Closes Omniome Buyout, Forays Into San Diego
by Zacks Equity Research
PacBio's (PACB) latest acquisition is expected to deliver a differentiated set of products and applications across a wide spectrum of markets.
Pacific Biosciences (PACB) Down 0.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain PacBio (PACB) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about PacBio (PACB) owing to its slew of strategic deals and strength in its Sequel system.
PacBio's (PACB) Q2 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
PacBio (PACB) sees strength in Q2 product revenues, led by robust consumable sales.
Pacific Biosciences of California (PACB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of -5.00% and 0.49%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Pacific Biosciences of California (PACB) Q2 Earnings Expected to Decline
by Zacks Equity Research
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PacBio (PACB) Enhances Sequencing Platform Via Latest Buyout
by Zacks Equity Research
PacBio's (PACB) latest acquisition is expected to deliver the most advanced blend of sequencing solutions to transform the genomics landscape.
Pacific Biosciences (PACB)-RCIGM Tie Up for Sequencing Research
by Zacks Equity Research
Pacific Biosciences' (PACB) latest research tie-up is likely to use HiFi Sequencing data on some of the most difficult cases of rare pediatric disease and provide insights into the treatment journey.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Pacific Biosciences (PACB) Down 10.8% Despite Narrower Q1 Loss
by Zacks Equity Research
Pacific Biosciences' (PACB) revenues grow in both its segments during the first quarter.
Pacific Biosciences of California (PACB) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Pacific Biosciences (PACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacific Biosciences (PACB) Down 30.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacific Biosciences' (PACB) Sequel II Gets Deployed by LabCorp
by Zacks Equity Research
Pacific Biosciences' (PACB) Sequel II HiFi sequencing gets utilized by LabCorp to detect SARS-COV-2 variants in the United States.
5 Stocks That Make Ark Innovation ETF (ARKK) Red Hot
by Sweta Killa
ARKK is centered around the idea of disruptive innovation, which is defined as the introduction of a technologically-enabled new product or service that potentially changes the way the world works.
Pacific Biosciences (PACB) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) suffers a Product revenue decline in the fourth quarter.
Pacific Biosciences of California (PACB) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of -102.33% and -0.05%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Pacific Biosciences' (PACB) Q4 Earnings?
by Zacks Equity Research
Pacific Biosciences' (PACB) fourth-quarter results are likely to reflect strength in its Sequel system.
Cigna (CI) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Cigna's (CI) fourth-quarter results are likely to reflect strong performance across the business portfolio and lower SG&A costs, partly offset by continued COVID-19 related expenses.
Accuray (ARAY) Releases Encouraging Breast Cancer Study Results
by Zacks Equity Research
Accuray (ARAY) releases positive data from a prospective trial of 338 women with low-risk breast cancer.
Why You Should Retain Pacific Biosciences (PACB) Stock Now
by Zacks Equity Research
Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of solid prospects.
Pacific Biosciences (PACB) Releases Preliminary Q4 Revenues
by Zacks Equity Research
Pacific Biosciences' (PACB) preliminary Q420 revenues are expected to improve from Q320.
3 MedTech Stocks Up Above 50% That Might Lose Steam in 2021
by Sriparna Ghosal
Due to the persistence of global manufacturing and supply-chain disruptions and a few other hostile externalities, three stocks are likely to register a dull 2021 performance.
Top ETF of December & Its Best Stocks
by Sweta Killa
We have highlighted the best ETF of December and its best performing stocks.